Category: Biolase Technology Inc.
Standard & Poor's gives Medtronic's long-term debt an "A+" rating; also, ICU Medical to re-state financials; Zynex details NeuroDyne buyout terms; GI Dynamics dips on huge volume; Report: JPMorgan testing the waters for Kai Medical IPO; Delcath inks French training deal for Chemosat device; Misonix signs Asian distribution deal; Premier inks urological device deals; plus, a Funding Roundup and analysts' ups and downs.
Standard & Poor's Ratings Services affirmed Medtronic's (NYSE:MDT) long-term debt's "A+" rating yesterday, after the med-tech titan announced another debt offering.
The rating agency said its view of Medtronic's senior unsecured notes and its stable rating outlook "reflect the company's 'strong' business risk profile and 'modest' financial risk profile."
Biolase Technology CEO Federico Pignatelli touts his $1 annual salary, calling on politicians and other corporate heads to reconsider their own wages, after the release of the company's Wall-Street-meeting 4th quarter earnings; also, Cooper Cos. posts double-digit sales, earnings increases; Delcath slashes 2011 losses; Cantel Medical's Q2 sales, earnings jump more than 20%; Zeltiq's 2011 sales rise 168% as it pares losses by 23%; Lower sales, losses for TranS1 in Q4 & 2011; and Photomedex swings to Q4, 2011 losses.
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street's 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
Biolase Technology CEO Federico Pignatelli touts his $1 annual salary, calling on politicians and other corporate heads to reconsider their own wages, after the release of the company's Wall-Street-meeting 4th quarter earnings.
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street's 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
Allezoe Medical Holdings says a board member and its corporate secretary broke company rules and maybe also state and federal laws when he wrote an affidavit supporting the plaintiff in a lawsuit against Allezoe; also, Biolase names a sales & marketing veep and SynCardia taps a new COO.
Allezoe Medical Holdings (OTC:ALZM) said board member and secretary Hyman White broke its internal rules and possibly state and federal laws when he wrote an affidavit supporting the un-named plaintiff in a lawsuit filed against Allezoe.
Edwards Lifesciences says it will re-state its financials for the 1st 3 quarters of 2011; also, worried that Medtronic's going to burn you?; Dehaier wins credit rating upgrade; InfuSystem taps advisor on "strategic alternatives," shares climb; GPOs: Nihon Koden, Freedom Medical ink deals with Premier; Miracor Medical lands $3.5M grant; Intuitive Surgical marks yet another high; CareFusion wins $44.7M infusion pump contract from the U.S. Defense Dept.; plus, a Deals Roundup and analysts' ups and downs.
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, "due to certain technical errors in the balance sheets and cash flow statements for these interim periods."
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.
GE Healthcare files the first module of a pre-market approval application for its Senographe Essential breast tomosynthesis device ; also, Maquet wins 510(k), CE Mark for CardioSave IABP; J&J's Ethicon Endo-Surgery gets 510(k) nod for Enseal G2 tissue sealers; and Cordis lands clearances for Empira dilation catheters.
GE Healthcare (NYSE:GE) filed the first module of its pre-market approval application for the breast tomosynthesis option of its Senographe Essential system.
The health care giant said the first submission included a device description and non-clinical information, including "phantom testing," and detector performance evaluation. The system is intended as an add-on option for the Senographe Essential to produce 3D images for screening and diagnosis of breast cancer.
CareFusion Corp.'s first-quarter profits rose 76 percent over 2011 numbers despite ventilator recall.
CareFusion Corp.'s (NYSE:CFN) first-quarter profits are up 76 percent from 2011 numbers for the three months ended Sept. 30, in spite of a recall of its Avea ventilators.
CareFusion posted profits of $67 million, or 30 cents per share, on a sales of $844 million for the quarter - a top-line increase of 4.1 percent compared with $811 million during the same period last year. But Q1 2011 profits were only $38 million, or 17 cents per share.
